Loading viewer...
report
Format: PDF report
This Public Assessment Report details the scientific discussion and approval process for Sorafenib Alvogen 200 mg, a treatment for hepatocellular and renal cell carcinoma.
report
CT Automotive Group
report
Deloitte
report
Pollmeier
report
Deloitte